Skip to content
Melanocortin Peptide

PT-141 (Bremelanotide)

The only peptide approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women (as Vyleesi). Unlike PDE5 inhibitors (Viagra, Cialis), PT-141 works centrally via melanocortin receptors in the brain - enhancing desire and arousal in both men and women regardless of cardiovascular input.

sexual-wellnessperformance
Tier B— Generally safe — moderate evidence
Evidence gradeA — Multiple RCTs / Meta-analysis
BH

Editorially reviewed by

BiohackingHub Research Team

Editorial Team · Last updated: March 25, 2026

What Makes PT-141 Unique

PT-141 (Bremelanotide) occupies a unique position in sexual wellness pharmacology: it is the only compound that targets the central nervous system to enhance sexual desire and arousal, rather than acting on peripheral vascular mechanisms like PDE5 inhibitors.

This distinction matters clinically. Sildenafil (Viagra) and tadalafil (Cialis) work by increasing blood flow to genitalia -- they require sexual stimulation to work and do nothing for desire or libido. PT-141 works at the level of the hypothalamus and limbic system, activating the neural circuits that generate sexual desire before any peripheral response occurs.

Mechanism of Action

  • Melanocortin receptor activation -- PT-141 is a non-selective melanocortin receptor agonist, activating primarily MC3R and MC4R receptors in the hypothalamus and limbic system
  • Dopaminergic activation -- melanocortin receptor stimulation triggers dopamine release in the nucleus accumbens, the brain's reward and motivation centre
  • Nitric oxide pathway (secondary) -- downstream from central activation, PT-141 also increases NO production in genital tissue, contributing to physical arousal alongside central desire
  • Works in both sexes -- unlike PDE5 inhibitors which primarily address erectile dysfunction, PT-141 demonstrates efficacy in clinical trials for both men and women

FDA Approval Context

The pharmaceutical version of PT-141 -- branded as Vyleesi (bremelanotide 1.75 mg/0.3 mL autoinjector) -- received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. This is the first and only FDA-approved treatment that works centrally for female sexual dysfunction.

Nausea Management

Nausea is the primary limiting side effect, occurring in 30-40% of users. Evidence-based mitigation strategies:

  1. Start at 0.5mg and titrate up based on tolerance
  2. Take 4mg ondansetron (Zofran) 30 minutes before PT-141 injection
  3. Eat a light meal 2 hours before administration
  4. Stay well hydrated

Important Safety Note

Bremelanotide transiently raises blood pressure and lowers heart rate after each dose. The FDA Vyleesi label contraindicates it in uncontrolled hypertension and known cardiovascular disease, limits use to one dose per 24 hours and eight per month, and does not list PDE5 inhibitors as a contraindication: the only published co-administration data is a small 2005 study of intranasal PT-141 with sildenafil in men with erectile dysfunction, which reported no new adverse events. Treat the combination as untested outside medical supervision, not as a documented hazard.

Stacking Interactions

How PT-141 (Bremelanotide) interacts with other compounds

+
OxytocinSynergisticweak evidence

Administer oxytocin intranasal 15-20 min before sexual activity, after PT-141 injection (which is given 45-60 min prior). Do not combine PT-141 with PDE5 inhibitors.

Protocols using PT-141 (Bremelanotide)

Evidence-graded stacks that include this compound

Safety Profile — Tier B

Generally safe — moderate evidence

Contraindications

  • ●Cardiovascular disease - PT-141 transiently raises blood pressure
  • ●Uncontrolled hypertension
  • ●Pregnancy
  • ●Combination with PDE5 inhibitors (Viagra, Cialis) is untested beyond one small study - only under medical supervision

Side Effects

  • ●Nausea - most common (30-40% of users), peaks at 60-90 min, resolves within 2 hours
  • ●Flushing and skin hyperpigmentation (dose-dependent)
  • ●Transient blood pressure increase (10-15 mmHg) lasting 30-60 minutes
  • ●Spontaneous erections in men (desired effect)
  • ●Mild fatigue post-dose

Drug Interactions

PDE5 inhibitors (Sildenafil, Tadalafil) - opposite blood pressure effects, combination studied only in one small trial; medical supervisionAntihypertensives - monitor blood pressureNitrates - contraindicated